X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company intends to use the net proceeds to further the development of GEM-SSI, GEM-AKI and GEM-CKD. REVTx-100 (phosphorylated hexaacyl disaccharide) is being developed as a potential therapy for prevention and treatment of hospital acquired infection.
Lead Product(s): Phosphorylated Hexaacyl Disaccharide
Therapeutic Area: Infections and Infectious Diseases Product Name: REVTx-100
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $6.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 05, 2024
Details:
The Company intends to use the net proceeds from this offering to further the development of GEM-SSI, GEM-AKI and GEM-CKD. REVTx-100 (phosphorylated hexaacyl disaccharide) is being developed as a potential therapy for prevention and treatment of hospital acquired infection.
Lead Product(s): Phosphorylated Hexaacyl Disaccharide
Therapeutic Area: Infections and Infectious Diseases Product Name: REVTx-100
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $6.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 01, 2024
Details:
REVTx-100 is being developed, through a license agreement with Vanderbilt University, as a potential therapy for the prevention or treatment of healthcare-associated bacterial infection including post-surgical infection, post-burn infection, urinary tract infection.
Lead Product(s): REVTx-100
Therapeutic Area: Infections and Infectious Diseases Product Name: REVTx-100
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2023
Details:
The Company intends to use the net proceeds from this offering to further the development of REVTx-100 and REVTx-300. REVTx-100 is being developed as a prevention and treatment of postoperative infection.
Lead Product(s): REVTx-100
Therapeutic Area: Infections and Infectious Diseases Product Name: REVTx-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $15.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 13, 2023
Details:
The Company intends to use the net proceeds from this offering to further the development of REVTx-100 and REVTx-300 including the (i) manufacturing of clinical supply of our drug product, to conduct, a combined Phase 1a clinical study for REVTx-100 and REVTx-300.
Lead Product(s): REVTx-100
Therapeutic Area: Infections and Infectious Diseases Product Name: REVTx-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $15.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 09, 2023
Details:
REVTx-300 is a inhibitor of TGF-b, formulated for systemic administration of PHAD and is being developed as a potential therapy for CKD, AKI, myocarditis and NASH.
Lead Product(s): REVTx-300
Therapeutic Area: Nephrology Product Name: REVTx-300
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
REVTx-300 is our proprietary formulation for systemic administration of PHAD and is being developed as a potential therapy for the treatment of acute and chronic organ disease including CKD, acute kidney injury (AKI), myocarditis, and NASH.
Lead Product(s): REVTx-300
Therapeutic Area: Nephrology Product Name: REVTx-300
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2022
Details:
REVTx-300 is proprietary formulation for systemic administration of PHAD and is being developed as a potential therapy for treatment of acute and chronic organ disease including chronic kidney disease, acute kidney injury (AKI), myocarditis, and nonalcoholic steatohepatitis.
Lead Product(s): REVTx-300
Therapeutic Area: Nephrology Product Name: REVTx-300
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
The Company intends to use the net proceeds from this offering to further the development of REVTx-99b; further development of REVTx-200 and REVTx-300; continue to develop other products and therapies; and fund working capital and general corporate purposes.
Lead Product(s): REVTx-99b
Therapeutic Area: Immunology Product Name: REVTx-99b
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 29, 2022
Details:
The Company intends to use the net proceeds from this offering to further the development of REVTx-99b, REVTx-200 and REVTx-300, and continue to develop other products and therapies, and fund working capital and general corporate purposes using any remaining amounts.
Lead Product(s): REVTx-99b
Therapeutic Area: Immunology Product Name: REVTx-99b
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
